Form 8-K - Current report:
SEC Accession No. 0001662774-25-000034
Filing Date
2025-06-05
Accepted
2025-06-05 16:12:42
Documents
12
Period of Report
2025-06-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K qncx-20250604.htm   iXBRL 8-K 44036
  Complete submission text file 0001662774-25-000034.txt   163375

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20250604.xsd EX-101.SCH 1785
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20250604_lab.xml EX-101.LAB 22534
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20250604_pre.xml EX-101.PRE 13048
14 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20250604_htm.xml XML 2836
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 251027236
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)